Atezolizumab, a PD-L1 inhibitor, in combination with bevacizumab, a VEGF-targeting antibody, has been approved by the U.S. Food and Drug Administration (FDA) as a first-line treatment for unresectable HCC [3]. Here, CD274 is linked to hepatocellular carcinoma.